EyePoint (EYPT) said Friday it filed a complaint in a Massachusetts court against Ocular Therapeutix (OCUL), alleging that Ocular made false or misleading claims about the company's lead eye-disease candidate, Duravyu.
The company said it is seeking to stop Ocular from making further false statements and to obtain a public retraction, according to a regulatory filing.
Ocular didn't immediately respond to MT Newswires' request for comment.
EyePoint shares were down 1.1% in premarket activity Monday, while Ocular fell 2.2%.